The Hope Paradox: 5-Year Outcomes for Psilocybin & Depression

Hope is easy to sell, but long-term outcomes are much harder to sustain. In this video, we review the newly published five-year follow-up study (Gukasyan et al., 2024) examining the effects of psilocybin-assisted therapy for people diagnosed with Major Depressive Disorder (MDD).

We bridge the gap between "selling hope" and "modern facilitation" by looking at how to move clients from the initial breakthrough into a fully supported daily practice.

🔬 WHAT WE BREAK DOWN:✨ The 5-Year Study: Remission and response rates years after the initial treatment.✨ Protocol vs. Reality: Comparing the original Johns Hopkins trial results to long-term durability.✨ The Integration Gap: How neuroplastic coaching and facilitator support turn "hope" into proven impact.✨ Clinical Insights: New perspectives on SSRI interactions and MDD recovery.

🕒 CHAPTERS:0:00 The Hope Paradox: Why Long-Term Outcomes Matter0:57 Study Breakdown: 5-Year Follow Up2:02 Protocol from Original Study3:17 Results of Original Study (1 Year)3:51 5-Year Follow Up Results5:33 Participant Feedback6:33 Integrated Facilitation Practice8:39 Closing the Loop: Turning Hope into Impact

📚 STUDY REFERENCED:Gukasyan et al., 2024. Five-Year Outcomes of Psilocybin-Assisted Therapy for Major Depressive Disorder. Journal of Psychedelic Studies.

🔗 CONNECT WITH ENTHEOGEN INSTITUTE:📩 Newsletter: https://mailchi.mp/bc97570b9ae9/subscribe🌐 Website: https://entheotraining.com🎓 Apply for Training: https://entheotraining.com/apply-now-1📸 Instagram: @entheogeninstitute

⚠️ EDUCATIONAL CONTENT DISCLAIMER:This video discusses peer-reviewed research and legally regulated psilocybin programs in Oregon and Colorado. This information is for educational purposes only and should not be considered medical advice. Always consult with a licensed facilitator or health care provider regarding your specific needs.